(Q33320029)

25 July 2017

title

Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis (English)

1 reference

25 July 2017

1 reference

6

Jan Palmblad

1 reference

25 July 2017

5

Bengt Fadeel

1 reference

25 July 2017

Eva Kimby

4

1 reference

ORCID Public Data File 2021

author name string

Daniel Tesfa

1

1 reference

25 July 2017

Tobias Gelius

2

1 reference

25 July 2017

Birgitta Sander

3

1 reference

25 July 2017

Hans Hägglund

7

1 reference

25 July 2017

publication date

16 February 2008

1 reference

25 July 2017

1 reference

25 July 2017

volume

25

1 reference

25 July 2017

issue

4

1 reference

25 July 2017

page(s)

374-379

1 reference

Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.

25 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12032-008-9049-Z

Elimination of senescent neutrophils by TNF-related apoptosis-inducing [corrected] ligand

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12032-008-9049-Z

Idiopathic, immune, infectious, and idiosyncratic neutropenias

21 January 2018

1 reference

12 December 2020

The therapeutic use of rituximab in non-Hodgkin's lymphoma

1 reference

12 December 2020

Pharmacogenetics and blood dyscrasias.

1 reference

12 December 2020

Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma

1 reference

12 December 2020

Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma

1 reference

12 December 2020

Kostmann syndrome or infantile genetic agranulocytosis, part two: Understanding the underlying genetic defects in severe congenital neutropenia

1 reference

12 December 2020

Rituximab treatment of refractory rheumatoid arthritis

1 reference

12 December 2020

Rituximab: a promising therapy in systemic lupus erythematosus

1 reference

12 December 2020

Reactive intermediates and the pathogenesis of adverse drug reactions: the toxicology perspective

1 reference

12 December 2020

B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis

1 reference

12 December 2020

Delayed-onset neutropenia associated with rituximab therapy

1 reference

12 December 2020

High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation

1 reference

12 December 2020

Kostmann syndrome or infantile genetic agranulocytosis, part one: celebrating 50 years of clinical and basic research on severe congenital neutropenia

1 reference

12 December 2020

Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments

1 reference

12 December 2020

Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases

1 reference

12 December 2020

[Rituximab: mechanism of action and resistance]

1 reference

12 December 2020

Tolerability and safety of rituximab (MabThera).

1 reference

12 December 2020

Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1

1 reference

12 December 2020

Severe congenital neutropenia

1 reference

12 December 2020

Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells

1 reference

12 December 2020

1 reference

12 December 2020

HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease)

1 reference

12 December 2020

Heterogeneous expression pattern of pro- and anti-apoptotic factors in myeloid progenitor cells of patients with severe congenital neutropenia treated with granulocyte colony-stimulating factor.

1 reference

12 December 2020

A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study

1 reference

12 December 2020

Neutropenia in patients treated with rituximab

1 reference

12 December 2020

10.1007/S12032-008-9049-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

25 July 2017

1036983640

0 references

1 reference